GUMM, NITE, VPHM.
Ron,
Thanks for your views on GUMM. I obtained a copy of the abstract that Dr. Hensley, co-developer of Zicam, presented at a medical conference in Corfu in April. This is the first time that the abstract has been released publicly outside the medical conference, and the results of the study, as described in the limited abstract, look quite conclusive. If the study is accepted by the New England Journal of Medicine, there's no telling how high the stock will trade. VPHM nearly quadrupled in the week that it's news came out, and Pleconaril isn't even as effective as Zicam, nor did its stock have a large short interest like GUMM. GumTech might also be close to announcing a joint venture to manufacture and distribute nicotine gum, and that should also have a big impact on the stock. I welcome both positive and negative feedback from everyone on the abstract.
beta.siliconinvestor.com
beta.siliconinvestor.com
NITE doesn't look very good to me. The stock closed below its lower daily bollinger band last Friday and also closed below recent lows on the weekly chart. If 24 doesn't hold, I think it has risk to 18. Gads, I hope that doesn't happen. The daily money flow was very bad last week, and accelerated each day as the stock closed lower. I don't like the look of the chart, although it might be a great buy based on fundamentals.
FWIW, VPHM has shown distribution between 28 and 29 on the daily chart. If it doesn't get through there soon, I wouldn't hold it. It's a dangerous short, but might make a good short term trade.
Dan |
